Breast cancer

封面

如何引用文章

全文:

详细

Breast cancer (BC) is a malignant tumor originating from the epithelium of the breast tissue. There is no single etiological factor in the development of breast cancer. In 3–10% of patients with breast cancer, the development of the disease is associated with the presence of mutations in the breast cancer gene (BRCA) 1, BRCA2, CHEK, NBS1, TP53. In other patients, breast cancer is sporadic.

作者简介

Liudmila Zhukova

Loginov Moscow Clinical Scientific Center

编辑信件的主要联系方式.
Email: zhukova@mknc.ru
ORCID iD: 0000-0003-4848-6938

D. Sci. (Med.)

俄罗斯联邦, Moscow

Iuliia Andreeva

Russian Medical Academy of Continuous Professional Education

Email: zhukova@mknc.ru

D. Sci. (Med.), Prof.

俄罗斯联邦, Moscow

Larisa Zavalishina

Russian Medical Academy of Continuous Professional Education

Email: zhukova@mknc.ru
ORCID iD: 0000-0002-0677-7991

D. Sci. (Biol.), Prof.

俄罗斯联邦, Moscow

Aziz Zakiriakhodzhaev

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: zhukova@mknc.ru

D. Sci. (Med.)

俄罗斯联邦, Moscow

Irina Koroleva

Medical University «Reaviz»

Email: zhukova@mknc.ru

D. Sci. (Med.), Prof.

俄罗斯联邦, Samara

Aleksei Nazarenko

Loginov Moscow Clinical Scientific Center

Email: zhukova@mknc.ru

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Ruslan Paltuev

Petrov National Medical Research Center of Oncology

Email: zhukova@mknc.ru
ORCID iD: 0000-0002-0871-9453

Senior Res. Officer

俄罗斯联邦, Saint Petersburg

Anastasiia Parokonnaia

Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University

Email: zhukova@mknc.ru
ORCID iD: 0000-0003-1710-0772

D. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow

Aleksandr Petrovskii

Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Sergei Portnoi

LLC «Frau Klinik»

Email: zhukova@mknc.ru

D. Sci. (Med.)

俄罗斯联邦, Moscow

Vladimir Semiglazov

Petrov National Medical Research Center of Oncology

Email: zhukova@mknc.ru
ORCID iD: 0000-0003-0077-9619

D. Sci. (Med.), Prof., Acad. RANS, Corr. Memb. RAS

俄罗斯联邦, Saint Petersburg

Tatiana Semiglazova

Petrov National Medical Research Center of Oncology; Mechnikov North-Western State Medical University

Email: zhukova@mknc.ru
ORCID iD: 0000-0002-4305-6691

D. Sci. (Med.)

俄罗斯联邦, Saint Petersburg; Saint Petersburg

Marina Stenina

Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru
ORCID iD: 0000-0001-5304-9682

D. Sci. (Med.)

俄罗斯联邦, Moscow

Aleksandra Stepanova

Diagnostic and Rehabilitation Center «Recovery»

Email: zhukova@mknc.ru

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Oxana Trofimova

Russian Medical Academy of Continuous Professional Education; Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru
ORCID iD: 0000-0002-7204-370X

D. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow

Sergey Tyulyandin

Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru

D. Sci. (Med.), Prof.

俄罗斯联邦, Moscow

Georgii Frank

Russian Medical Academy of Continuous Professional Education

Email: zhukova@mknc.ru

D. Sci. (Med.), Prof., Acad. RAS

俄罗斯联邦, Moscow

Mona Frolova

Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Iuliana Shatova

Rostov Research Institute of Oncology

Email: zhukova@mknc.ru

D. Sci. (Med.)

俄罗斯联邦, Rostov-on-Don

Aleksei Nevol’skikh

Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center

Email: zhukova@mknc.ru

D. Sci. (Med.)

俄罗斯联邦, Obninsk

Sergei Ivanov

Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center

Email: zhukova@mknc.ru

D. Sci. (Med.), Prof. RAS

俄罗斯联邦, Obninsk

Zhanna Khailova

Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center

Email: zhukova@mknc.ru

Cand. Sci. (Med.)

俄罗斯联邦, Obninsk

Tigran Gevorkian

Blokhin National Medical Research Center of Oncology

Email: zhukova@mknc.ru

deputy director

俄罗斯联邦, Moscow

参考

  1. Высоцкая И.В. Эндокринно-чувствительные опухоли репродуктивной системы. Руководство для врачей. М.: Специальное издательство медицинских книг (СИМК), 2014 [Vysotskaya IV. Endocrine-sensitive tumors of the reproductive system. A guide for doctors. Moscow: Special publishing house of medical books (SIMK), 2014 (in Russian)].
  2. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2018 [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. AD Kaprin, VV Starinsky, GV Petrova. Moscow: MNIOI them. P.A. Herzen – branch of the FSBI «NMIRC» of the Ministry of Health of Russia, 2018 (in Russian)].
  3. Agarwal I, Blanco L. WHO classification. PathologyOutlines.com website. Режим доступа: http://www.pathologyoutlines.com/topic/breastmalignantwhoclassification.html
  4. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition (UIJCC).
  5. Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw 2014; 12 (4): 542–90.
  6. Hassan LM, Mahmoud N, Miller AB, et al. Evaluation of effect of self-examination and physical examination on breast cancer. Breast 2015; 24 (4): 487–90. doi: 10.1016/j.breast.2015.04.011
  7. Liu X, Meng QH, Ye Y. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. NCBI 2015; 36 (2): 243–8.
  8. Elyasinia F, Keramati MR, Ahmadi F. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. Acta Med Iran 2017; 55 (4): 228–32.
  9. Vernieri C, Mennitto A, Prisciandaro M, Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Sci Rep 2018; 8 (1): 8703. doi: 10.1038/s41598-018-27075-z
  10. Lindkær-Jensen S, Larsen S, Habib-Lindkær-Jensen N, et al. Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance. Drug Des Devel Ther 2015; 9: 1481–90. doi: 10.2147/DDDT.S80451
  11. Tas F, Kilic L, Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer. Tumour Biol 2014; 35 (6): 5985–92. doi: 10.1007/s13277-014-1793-4
  12. Pedersen LM., Sørensen PG. Increased urinary albumin excretion rate in breast cancer patients. Acta Oncol Stockh Swed 2000; 39 (2): 145–9.
  13. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134 (7): e48-72. doi: 10.1043/1543-2165-134.7.e48
  14. Wolff AC, Hale Hammond ME, Allison KH, et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract 2018; 14 (7): 437–41.
  15. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379 (22): 2108–21.
  16. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929–40. doi: 10.1056/NEJMoa1813904
  17. Regan MM. Predicting Benefit of Endocrine Therapy for Early Breast Cancer. Breast. 2015; 24 (0 2): S129–S131.
  18. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32 (35): 3948–58.
  19. Bernhard J. et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2014; 32: 557–557.
  20. Viale G, Regan MM, Dell’Orto P, et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22 (10): 2201–7.
  21. Zhang X-H, Xiao C. Diagnostic Value of Nineteen Different Imaging Methods for Patients with Breast Cancer: a Network Meta-Analysis. Cell Physiol Biochem 2018; 46 (5): 2041–55.
  22. Myers RE, Johnston M, Pritchard K, et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001; 164 (10): 1439–44.
  23. Crump M, Goss PE, Prince M, et al. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996; 14 (1): 66–9.
  24. Rayter Z, Gazet JC, Shepherd J, et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol 1994; 20 (2): 134–40.
  25. Kosmin M, Makris A, Joshi PV, et al. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer 2017; 77: 109–16.
  26. Wang M, He X, Chang Y, et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta- analysis. Breast 2017; 31: 157–66.
  27. Petrelli F, Viale G, Cabiddu M, Barni S, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 2015; 153 (3): 477–91.
  28. Wülfing P, Borchard J, Bürger H, et al. Prognostic value of HER2-positive circulating tumor cells in breast cancer patients. Cancer Res 2006; 66 (8 Suppl.): 458–9.
  29. Noordhoek I, de Groot AF, Cohen D, et al. Higher ER load is not associated with better outcome in stage 1–3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. Breast Cancer Res Treat 2019; 176 (1): 27–36.
  30. Barco I, Chabrera C, García-Fernández A, et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound- guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients. Clin Transl Oncol 2017; 19 (6): 704–10.
  31. Yu Y-H, Mo Q-G, Zhu X, et al. Axillary fine needle aspiration cytology is a sensitive and highly specific technique for the detection of axillary lymph node metastasis: a meta-analysis and systematic review. Cytopathology 2016; 27 (1): 59–69.
  32. Wang X-W, Xiong Y-H, Zen X-Q, et al. Diagnostic accuracy of ultrasonograph guided fine-needle aspiration cytologic in staging of axillary lymph node metastasis in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev 2012; 13 (11): 5517–23.
  33. Liikanen J, Leidenius M, Joensuu H, et al. Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: Biopsy method and breast cancer outcome. Eur J Surg Oncol 2016; 42 (1): 64–70.
  34. Scully OJ, Bay B-H, Yip G, et al. Breast cancer metastasis. Cancer Genomics Proteomics 2012; 9 (5): 311–20.
  35. Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2016; 14 (3): 324–54.
  36. Стенина М.Б., Жукова Л.Г., Королева И.А. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. 2018; 8: 113–44 [Stenina MB, Zhukova LG, Koroleva IA. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu invazivnogo raka molochnoi zhelezy. Zlokachestvennye opukholi. 2018; 8: 113–44 (in Russian)].
  37. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26 (8): 1533–46.
  38. Du Rusquec Pauline, Blonz C, Frenel JS, Campone M. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Therapeutic Advances in Medical Oncology 2020; 12: 175.
  39. Fares J, Deepak K, Rashidi A, et al. Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clin Breast Cancer 2019; 19 (6): 383–91.
  40. Arab C, Vanderlei LCM, da Silva PL, et al. Cardiac autonomic modulation impairments in advanced breast cancer patients. Clin Res Cardiol 2018; 107 (10): 924–36.
  41. García-Manero M, Royo MP, Espinos J, et al. Pregnancy associated breast cancer. Eur J Surg Oncol 2009; 35 (2): 215–8.
  42. Peccatori FA, Azim HA, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl.) 6: vi160–170.
  43. Stensheim H, Cvancarova M, Møller B, et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer 2011; 129 (5): 1225–36.
  44. Shachar SS, Gallagher K, McGuire K, et al. Multidisciplinary Management of Breast Cancer During Pregnancy. Oncologist 2017; 22 (3): 324–34.
  45. Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 2002; 194 (1): 54–64.
  46. NCCN Clinical Practice Guidelines in Oncology for Older Adult Oncology. National Comprehensive Cancer Network. 2019. Available at: https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=1578. Accessed: 18.12.2019.
  47. Ferreira Poloni P, Vespoli HL, Almeida-Filho BS, et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study. Climacteric. 2017; 20 (5): 491–7.
  48. Budach W, Matuschek C, Bölke E, et al. DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 2015; 191 (8): 623–33.
  49. Wang G-L, Tsikouras P, Zuo HQ, et al. Radioactive seed localization and wire guided localization in breast cancer: A systematic review and meta-analysis. J BUON 2019; 24 (1): 48–60.
  50. Serban M, Lambert C, Ruo R, et al. Computed tomography-based virtual simulation versus ultrasound-based clinical setup in electron breast boost radiotherapy: Methodology for CT-based electron virtual simulation. Phys Med 2019; 67: 100–6.
  51. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC). Int J Radiat Oncol Biol Phys 2010; 76 (3): 120–45.
  52. ICRU Report 50, Report 62. Journal of the ICRU Issueded: 1 November 1999; ICRU Report 83. J ICRU 2010; 10 (1).
  53. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network. J Natl Compr Canc Netw 2020; 18 (4): 452–78.
  54. Cardoso F, Kyriakides S, Ohno S. ESMO Clinical Practice Guidelines. Early Breast Cancer. ESMO 2019; 30 (8): 1194–220.
  55. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009; 27 (10): 1615–20.
  56. Rizki H, Nkonde C, Ching RC, et al. Plastic surgical management of the contralateral breast in post-mastectomy breast reconstruction. Int J Surg 2013; 11 (9): 767–72.
  57. Kirby AN, Jena R, Harris EJ, et al. Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers? Radiother Oncol 2013; 106 (2): 231–5.
  58. Naoura I, Mazouni C, Ghanimeh J, et al. Factors influencing the decision to offer immediate breast reconstruction after mastectomy for ductal carcinoma in situ (DCIS): The Institut Gustave Roussy Breast Cancer Study Group experience. Breast 2013; 22 (5): 673–5.
  59. Thiessen FEF, Tjalma WA A, Tondu T. Breast reconstruction after breast conservation therapy for breast cancer. Eur J Obstet Gynecol Reprod Biol 2018; 230: 233–8.
  60. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23 (30): 7703–20.
  61. Iida S, Shunsuke H, Koji Y, et al. Evaluation of sentinel lymph node biopsy in clinically node-negative breast cancer. J Nippon Med 2011; 78 (2): 96–100.
  62. Huang TW, Kuo KN, Chen KH, et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system. Int J Surg 2016; 34: 73–80.
  63. Clements K, Dodwell D, Lawrence G, et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ. Eur J Surg Oncol 2015; 41 (10): 1406–10.
  64. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24 (21): 3381–7.
  65. Shurell E, Olcese C, Patil S, et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer 2018; 124 (1): 46–54.
  66. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012; 10: CD007847.
  67. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol 2019; 37 (19): 1629–37.
  68. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016; 387 (10021): 849–56.
  69. Glechner A, Wöckel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer 2013; 49 (4): 812–25.
  70. Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet 2012; 13 (4): 412–19.
  71. Moran MS, Schnitt SJ, Giuliano AE, et al. SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys 2014; 88 (3): 553–64.
  72. Povoski S, Jimenez RE, Wang WP, Xu RX. Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer. BMC Cancer 2009; 9 (1): 254.
  73. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017; 318 (10): 918–26.
  74. Libson S, Perez E, Takita C, Avisar E. Post Mastectomy Radiation for Stage II Breast Cancer Patients with T1/T2 Lesions. Eur J Breast Health 2019; 15 (2): 71–5.
  75. Abdulkarim BS, Cuartero J, Hanson J. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant RT compared with breast conserving therapy. J Clin Oncol 2011; 29: 2852–8.
  76. Jagsi R, Raad RA, Goldberg S. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy radiation. Inst J Radiat Oncol Biol Phys 2005; 62: 1035–9.
  77. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16): 1233–41.
  78. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–16.
  79. Collaborative G, Darby S, McGale P. Early Breast Cancer Trialists. Effect of radiotherapy after breast -conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378 (1707): 1716–1716.
  80. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16 (1): 47–56.
  81. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast- conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009; 27 (30): 4939–47. doi: 10.1200/JCO.2008.21.5764
  82. Haviland JS, Owen JL, Dewar J. The UK Standartisation of Breast Radiotherapy hypofractionination for treatment (START) of early breast-cancer: 10-year follow-up results of two randomized controlled trials. Lancet Oncol 2013; 14: 1086–94.
  83. Li YF, Chang L, Li WH, et al. Radiotherapy Concurrent Versus Sequential With Endocrine Therapy in Breast Cancer: A Meta-Analysis. Breast 2016; 27: 93–8.
  84. Mignot F, Ajgal Z, Xu H, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. Radiother Oncol 2017; 124 (2): 190–9.
  85. Buszek SM, Lin HY, Bedrosian I, et al. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys 2019; 105 (4): 795–802.
  86. Budach W, Bölke E, Kammers K, et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials – an update. Radiat Oncol 2015; 10: 258.
  87. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347 (16): 1227–32.
  88. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16): 1233–41.
  89. Li YF, Chang L, Li WH, et al. Radiotherapy Concurrent Versus Sequential With Endocrine Therapy in Breast Cancer: A Meta-Analysis. Breast 2016; 27: 93–8.
  90. Rowell NP. Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review. Radiother Oncol 2009; 91 (1): 23–32.
  91. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl J Med 2008; 358 (16): 1663–71.
  92. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24 (9): 2206–23.
  93. Tashima R, et al. P260 Evaluation of PgR expression as a prognostic factor in luminal HER2- negative breast cancer. Breast 2015; 24: S116.
  94. Citron ML, Berry DA, Cirrincione C, et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. J Clin Oncol 2005; 23 (16_Suppl.): 620–620.
  95. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28 (8): 1700–12.
  96. Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30 (10): 1541–57.
  97. Goldhirsch A, Colleoni M, Coates AS, et al. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol 1998; 9 (5): 489–93.
  98. Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27 (8): 1177–83.
  99. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8 (9): 1483–96
  100. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352 (22): 2302–13.
  101. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node- positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24 (36): 5664–71.
  102. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100 (11): 805–14.
  103. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673–84.
  104. Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 2013; 14 (11): 1121–8.
  105. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372 (2): 134–41.
  106. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (1): 25–32.
  107. Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020; 38 (3): 203–13.
  108. Стенина М.Б., Жукова Л.Г., Королева И.А., и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. Практические рекомендации RUSSCO. 2019; 9 (#3s2): 128–63 [Stenina MB, Zhukova LG, Koroleva IA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu invazivnogo raka molochnoi zhelezy. Zlokachestvennye opukholi. Prakticheskie rekomendatsii RUSSCO. 2019; 9 (#3s2): 128–63 (in Russian)].
  109. Jones SE, Savin MA, Holmes FA, et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. J Clin Oncol 2006; 24 (34): 5381–7.
  110. Van Rossum AGJ, Kok M, van Werkhoven E, et al. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). Eur J Cancer 2018; 102: 40–8.
  111. Watanabe T, Kuranami M, Inoue K, et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 2017; 123 (5): 759–68.
  112. Ferreira Filho AF, Di Leo A, Paesmans M, et al. The feasibility of classical cyclophosphamide, methotrexate, 5- fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. Ann Oncol 2002; 13 (3): 416–21.
  113. Von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380 (7): 617–28.
  114. Jones RL, Walsh G, Ashley S, et al. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009; 100 (2): 305–10. doi: 10.1038/sj.bjc.6604862
  115. Kosaka Y, Rai Y, Masuda N, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015; 23 (4): 1137–43.
  116. Gilbar P, McPherson I, Sorour N, et al. High incidence of febrile neutropenia following adjuvant breast chemotherapy with docetaxel, carboplatin and trastuzumab. Breast Cancer Management 2014; 3 (4): 327–33.
  117. Итоговый отчет о результатах клинического исследования «Международное многоцентровое двойное слепое рандомизированное исследование эффективности и безопасности однократного применения препарата BCD-017 по сравнению с ежедневным введением филграстима с целью профилактики нейтропении у больных раком молочной железы, получающих миелосупрессивную химиотерапию, с двойным маскированием». 31.10.2014 [Itogovyi otchet o rezul’tatakh klinicheskogo issledovaniia «Mezhdunarodnoe mnogotsentrovoe dvoinoe slepoe randomizirovannoe issledovanie effektivnosti i bezopasnosti odnokratnogo primeneniia preparata BCD-017 po sravneniiu s ezhednevnym vvedeniem filgrastima s tsel’iu profilaktiki neitropenii u bol’nykh rakom molochnoi zhelezy, poluchaiushchikh mielosupressivnuiu khimioterapiiu, s dvoinym maskirovaniem». 31.10.2014 (in Russian)].
  118. Zidan J, Hussein O, Abzah A, et al. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. Med Oncol 2008; 25 (3): 274–8.
  119. Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008; 26 (8): 1216–22.
  120. Von Minckwitz G, Procter M, de Azambuja E. Adjuvant Pertuzumab and Trastuzumab in Early HER2 Positive Breast Cancer. N Engl J Med 2017; 377 (2): 122–31.
  121. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14): 1273–83. doi: 10.1056/NEJMoa0910383
  122. Slamon DJ, Eiermann W, Robert NJ, et al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Res 2016; 76 (Suppl.4): S5-04-S5-04.
  123. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29 (25): 3366.
  124. Gligorov J, Ataseven B, Verrill M, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study»s primary analysis of 2573 patients. Eur J Cancer 2017; 82: 237–46.
  125. Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncology 2019; 5 (5): e190339–e190339.
  126. Ribi K, Luo W, Bernhard J, et al. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 2016; 34 (14): 1601–10.
  127. Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol 1999; 43 (6): 461–6.
  128. Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012; 23: 882–90.
  129. Davies C, Pan H, Godwin J, et al. Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long- term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381 (9869): 805–16.
  130. Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016; 34: 2221–31.
  131. Gray RG, Quirke P, Handley K, et al. aTTom Collaborative Group. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (18_Suppl.): 5–5.
  132. Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer treatment reviews 2010; 36 (3): 249–61.
  133. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006; 94 (4): 460–4.
  134. Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease- free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006; 7 (5): 416–21.
  135. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007; 99: 1845–53.
  136. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase- inhibitor adjuvant therapy to 10 years. N Engl J Med 2016; 375: 209–19.
  137. Karakatsanis A, Tasoulis MK, Wärnberg F, et al. Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. Br J Surg 2018; 105 (5): 469–81.
  138. Criscitiello C, Golshan M, Barry WT, et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. Eur J Cancer 2018; 97: 1–6.
  139. Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol 2014; 25 (6): 1079–85.
  140. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15 (7): 2483–93.
  141. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16 (1): 93–100.
  142. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer – 10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76 (8): 1099–105.
  143. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26 (8): 1275–81.
  144. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–72.
  145. Allevi G, Strina C, Andreis D, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer 2013; 108 (8): 1587–92.
  146. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99 (2): 167–70.
  147. Dowsett M. PG 8.02 Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints. Breast 2015; 24: S14.
  148. Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 2015; 26 (7): 1280–91.
  149. Glück S, de Snoo F, Peeters J, et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013; 139 (3): 759–67.
  150. Suleman K, Almalik O, Haque E, et al. Does the Timing of Surgery after Neoadjuvant Therapy in Breast Cancer Patients Affect the Outcome? Oncology 2020; 98 (3): 168–73.
  151. Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. Eur J Surg Oncol 2017; 43 (4): 613–8.
  152. Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat 2017; 165 (3): 593–600.
  153. Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German breast group. J Clin Oncol 2005; 23: 2676–85.
  154. Sikov WM, Berry DA, Perou CM, et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once per Week Paclitaxel Followed by Dose Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol 2014; 33 (1): 13–21.
  155. Spring L, Niemierko A, Comander AH, et al. Tolerability and effectiveness of pertuzumab containing neoadjuvant (NA) regimens vs. AC TH for HER2 positive (+) localized breast cancer (BC) [ASCO abstr. 586]. J Clin Oncol 2016; p. 34.
  156. Sugitani I, Ueda S, Sakurai T, et al. Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety. Int J Clin Oncol 2017; 22 (5): 880–6.
  157. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24 (9): 2278–84.
  158. Hussain N, Said ASA, Khan Z. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer 2018; 2018: 6106041.
  159. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta- analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet Lond Engl 2019; 393 (10179): 1440–52.
  160. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (13): 1317–25.
  161. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35 (18): 2062–81.
  162. Shen J, Valero V, Buchholz TA, et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004; 11 (9): 854–60.
  163. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative «Arimidex» Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106 (10): 2095–103.
  164. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2018.
  165. Debiasi M, Polanczyk CA, Ziegelmann P, et al. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 2018; 8: 156.
  166. Loughney L, West MA, Kemp GJ, et al. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: A systematic review. Eur J Surg Oncol 2016; 42 (1): 28–38.
  167. Newman LA. Management of patients with locally advanced breast cancer. Curr Oncol Rep 2004; 6 (1): 53.
  168. Sun Y, Liao M, He L, Zhu C. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2017; 96 (43): e8367.
  169. Liu J, Mao K, Jiang S, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II–III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget 2016; 7 (17): 24848–59.
  170. Valagussa P, Zambetti M, Bignami P, et al. T3b-T4 breast cancer: factors affecting results in combined modality treatments. Clin Exp Metastasis 1983; 1 (2): 191–202.
  171. Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol 2018; 126 (1): 177–80.
  172. Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008; 22 (6): 614–23; discussion 623, 627–9.
  173. Cardoso F, Paluch-Shimon S, Senkus E, et.al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31 (12): 1623–49.
  174. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. Jama 2017; 317 (1), 48–58.
  175. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038–44.
  176. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7.
  177. Von Moos R, Body JJ, Rider A, et al. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol 2018; 11: 1–9.
  178. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double- blind study. J Clin Oncol 2010; 28: 5132–9.
  179. Kuss JT, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 1997; 42 (3): 265–74.
  180. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34 (25): 3069–103.
  181. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19 (2): 343–53.
  182. Tomas E, Kauppila A, Blanco G, et al. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995; 59 (2): 261–6.
  183. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28 (30): 4594–600.
  184. Thürlimann B, Hess D, Köberle D, et al. Anastrozole («Arimidex») versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 – A sub-study of the TARGET (Tamoxifen or «Arimidex» Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85: 247–54.
  185. Iwata H, Im SA, Masuda N, et al. PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy – Safety and efficacy in Asian patients. J Global Oncol 2017; 3 (4): 289–303.
  186. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. New Engl J Med 2018; 379 (20): 1926–36.
  187. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New Engl J Med 2020; 382 (6): 514–24.
  188. Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35 (25): 2875–84.
  189. Sledge GW, Toi M, Neven P, et al. MONARCH 2: overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer. Ann Oncol 2019; 30 (856).
  190. Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2- negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019; 174 (3): 719–29.
  191. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018; 29 (7): 1541–7.
  192. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019; 5 (1): 1–8.
  193. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000: 18 (11): 2234–44.
  194. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Advanc Ther 2013; 30 (10): 870–84.
  195. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017; 23 (17): 5218–24.
  196. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17 (8): 2341–54.
  197. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14 (4): 1146–55.
  198. Horiguchi J, Oyama T, Koibuchi Y, et al. Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer. Anticancer Res 2009; 29 (2): 517–24.
  199. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. J Clin Oncol 2001; 19 (10): 2587–95.
  200. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23 (24): 5542–51.
  201. Dieras V, Chevallier B, Kerbrat P, et al. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74 (4): 650–6.
  202. Ruiz M, Salvador J, Bayo J, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62 (6): 1085–90.
  203. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23 (31): 7794–803.
  204. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357 (26): 2666–76.
  205. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28 (20): 3239–47.
  206. Hurvitz SA, Allen HJ, Moroose RL, et al. A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clin Breast Cancer 2010; 10 (4): 307–12.
  207. Park JH, Im SA, Byun JM, et al. Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. J Breast Cancer 2017; 20 (4): 347–55.
  208. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155–61.
  209. Seo HY, Lee HJ, Woo OH, et al. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer. Invest New Drugs 2011; 29: 360–5.
  210. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35–40.
  211. Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2009; 9 (3): 178–83.
  212. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy. Gan To Kagaku Ryoho 2006; 33 (6): 761–6.
  213. Yardley DA, Brufsky A, Coleman RE, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015; 16 (1): 575.
  214. Sharma P, Kimler BF, Ward C, et al. Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy. J Clin Oncol 2016; 34 (15_Suppl.): 1015–1015.
  215. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018; 24 (5): 628–37.
  216. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13 (1): 73–80.
  217. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25 (23): 3407–14.
  218. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28 (20): 3256.
  219. Pivot X, Im SA, Guo M, Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370–4.
  220. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30 (4): 558–66.
  221. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New Engl J Med 2018; 379 (8): 753–63.
  222. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23 (19): 4265–74.
  223. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast 48cancer: the HERNATA study. J Clin Oncol 2011; 29: 264–71.
  224. Farhat F, Kattan JG, Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Cancer Chemother Pharmacol 2016; 77 (5): 1069–77.
  225. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853–8.
  226. Yardley DA, Burris HA, Simons L, et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 2008; 8 (5): 425–31.
  227. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 6 (1): 1–8.
  228. Tolaney SM, Najita J, Sperinde J, et al. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2013; 24 (7): 1841–7.
  229. Wilks S, Puhalla S, O’Shaughnessy J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clinical Breast Cancer 2014; 14 (6): 405–12.
  230. Yuan P, Ai P, Liu Y, et al. Efficacy of oral etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study. Medicine 2015; 94: 17.
  231. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 2015; 372 (8): 724–34.
  232. Miles D, Puglisi F, Schneeweiss A, et al. 1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Eur J Cancer. 2015: 51: S271.
  233. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012; 367 (19): 1783–91.
  234. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006; 355 (26): 2733–43.
  235. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in woman with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28 (7): 1124–30.
  236. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor–positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27 (33): 5529–37.
  237. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer. Oncologist 2010; 15 (2): 122–9.
  238. Johnston SRD, Hegg R, Im SA, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE. J Clin Oncol 2017; 36 (8): 741–8.
  239. Gradishar WJ, Hegg R, Im S-A, et al. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. J Clin Oncol 2017; 35 (15_Suppl.): 1004–1004.
  240. Miles D, Im YH, Fung A, et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol 2017; 28 (11): 2761–7.
  241. Mast ME, Vredeveld EJ, Credoe HM, et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Breast Cancer Res Treat 2014; 148 (1): 33–9.
  242. Stick LB, Yu J, Maraldo MV, et al. Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys 2017; 97 (4): 754–61.
  243. Meneses KD, McNees P, Loerzel VW, et al. Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors. Oncol Nurs Forum 2007; 34 (5): 1007–16.
  244. Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2005; 23 (25): 6027–36.
  245. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med 2006; 29 (1): 17–27.
  246. Golant M, Altman T, Martin C. Managing cancer side effects to improve quality of life: a cancer psychoeducation program. Cancer Nurs 2003; 26 (1): 37–44; quiz 45–6.
  247. Chung C, Lee S, Hwang S, Park E. Systematic review of exercise effects on health outcomes in women with breast cancer. Asian Nurs Res 2013; 7 (3): 149–59.
  248. Ebid AA, El-Sodany AM. Long-term effect of pulsed high-intensity laser therapy in the treatment of post-mastectomy pain syndrome: a double blind, placebo-control, randomized study. Lasers Med Sci 2015; 30 (6): 1747–55.
  249. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology 2013; 46 (1): 1–11.
  250. Yuste Sánchez MJ, Lacomba MT, Sánchez BS, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ 2010; 340.
  251. Finnane A, Janda M, Hayes SC. Review of the evidence of lymphedema treatment effect. Am J Phys Med Rehabil 2015; 94 (6): 483–98.
  252. Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 2002; 95 (11): 2260–7.
  253. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer 2003; 98 (6): 1114–22.
  254. Ahmed Omar MT, Abd-El-Gayed Ebid A, El Morsy AM. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study. J Surg Res 2011; 165 (1): 82–90.
  255. Piller NB, Douglass J, Heidenreich B, et al. Placebo controlled trial of mild electrical stimulation. J Lymphoedema 2010; Lymphoedema 5.1 (2010): 15–2.
  256. Jahr S, Schoppe B, Reisshauer A. Effect of treatment with low-intensity and extremely low- frequency electrostatic fields (Deep Oscillation) on breast tissue and pain in patients with secondary breast lymphoedema. J Rehabil Med 2008; 40 (8): 645–50.
  257. Грушина Т.И. Реабилитация пациенток после радикального лечения первичного рака молочной железы с помощью методов физической терапии. Физиотерапия, бальнеология, реабилитация. 2011; 2: 11–7 [Grushina TI. Reabilitatsiia patsientok posle radikal’nogo lecheniia pervichnogo raka molochnoi zhelezy s pomoshch’iu metodov fizicheskoi terapii. Fizioterapiia, bal’neologiia, reabilitatsiia. 2011; 2: 11–7 (in Russian)].
  258. Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. Cancer 2007; 109 (10): 1949–56.
  259. Smith TJ, Davidson NE, Schapira DV, et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17 (3): 1080–2.
  260. Llombart A, Frassoldati A, Paija O, et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin BreastCancer 2012; 12 (1): 40–8.
  261. Goodwin PJ. PG 6.03 Obesity and insulin resistance: clinical relevance and research priorities. Breast 2015; 24: S11–S12.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Block diagram of diagnostics and treatment of breast cancer patient.

下载 (121KB)
索引源数据
3. Fig. 2. Recommended algorithm of therapeutic and diagnostic measures depending on the clinical group of breast cancer.

下载 (187KB)
索引源数据
4. Fig. 3. Recommended sequence of different methods of adjuvant therapy.

下载 (59KB)
索引源数据
5. Fig. 4. Recommended tactics for the treatment of primary operable breast cancer (T2N0M0, T2N1M0, T3N0M0, T3N1M0) in the case of neoadjuvant drug therapy.

下载 (138KB)
索引源数据
6. Fig. 5. Recommended sequence of use of different types of treatment in the case of neoadjuvant therapy.

下载 (116KB)
索引源数据
7. Fig. 6. Recommended tactics for the treatment of locally advanced primary inoperable breast cancer (T0N2M0, T1N2M0, T2N2M0, T3N2M0, T4N0-2M0, T1-4N3M0).

下载 (137KB)
索引源数据
8. Fig. 7. Algorithm for choosing therapy for luminal breast cancer in menopausal patients and women of reproductive age receiving ovarian suppression, depending on the previous treatment and its effectiveness.

下载 (267KB)
索引源数据
9. Fig. 8. Recommended algorithm of drug therapy for metastatic hormone-dependent breast cancer.

下载 (59KB)
索引源数据

版权所有 © Consilium Medicum, 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##